Reviva Pharmaceuticals Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Brilaroxazine is advancing to a second phase III trial for schizophrenia, with FDA feedback on a new formulation and patent extension expected mid-year. The patent strategy could extend exclusivity to 2046, enhancing value and partnership prospects. Preparations for the next trial are complete, with rapid enrollment anticipated.
-
Brilaroxazine showed robust, sustained efficacy and a favorable safety profile in schizophrenia, with significant improvements in negative symptoms and low relapse rates. An additional phase 3 trial, required by the FDA, is set to begin soon, targeting NDA submission in late 2027.
Fiscal Year 2025
-
Brilaroxazine demonstrated robust efficacy, safety, and adherence in late-stage trials for schizophrenia, with strong expert endorsement of its differentiated profile and potential to address key unmet needs. FDA feedback in December will determine regulatory path.
-
The conference highlighted brilaroxazine's strong Phase 3 data in schizophrenia, with robust efficacy for negative symptoms, a favorable safety profile, and low discontinuation rates. Regulatory plans target an NDA filing in 2026, with competitive advantages over other late-stage assets.
-
Brilaroxazine demonstrated sustained efficacy in both positive and negative symptoms of schizophrenia over 12 months, with minimal weight gain, improved metabolic and hormonal profiles, and high adherence. Biomarker data suggest neuroprotective effects, and the safety profile is favorable compared to existing antipsychotics.
-
Brilaroxazine, a next-generation antipsychotic, demonstrated robust efficacy and safety in phase III trials for schizophrenia, with significant improvements in negative symptoms, neuroinflammation, and treatment adherence. NDA submission is targeted for end of 2026.
-
Brilaroxazine showed robust efficacy and safety in phase III schizophrenia trials, with low discontinuation and strong biomarker support. The drug's unique mechanism and anti-inflammatory effects position it for expansion into other neuropsychiatric and inflammatory indications.
-
Brilaroxazine demonstrated robust efficacy and safety in phase 3 schizophrenia trials, with lower discontinuation rates and significant improvements in negative symptoms compared to other antipsychotics. The company plans to expand indications and expects NDA submission in Q2 2026.
-
Brilaroxazine, a novel antipsychotic in phase III, showed robust efficacy and safety in treating schizophrenia, especially negative symptoms, with a 10-point separation from placebo and strong anti-inflammatory effects. NDA submission is planned for Q2 2026.
Fiscal Year 2024
-
Brilaroxazine demonstrated robust efficacy and safety in phase III schizophrenia trials, with rapid improvements across symptom domains and lower discontinuation rates. Vocal biomarker analysis provided objective validation and may support regulatory and clinical differentiation.